Related Experiment Video
Updated: Aug 30, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
HIV and hepatitis C virus: facts and controversies
G Borgia1, L Reynaud, I Gentile
1Dept. of Public Medicine and Social Security, Institute for Infectious Diseases-Ed 18, Federico II University of Naples, via Pansini 5, I-80131 Naples, Italy. borgia@unina.it
Insights
Hepatitis C virus (HCV) infection significantly impacts HIV-positive individuals, accelerating disease progression. Effective treatment strategies for HIV/HCV coinfection are crucial, especially considering the influence of highly active antiretroviral therapy (HAART).
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Hepatitis C virus (HCV) coinfection is prevalent in HIV-seropositive individuals, particularly among drug abusers.
- HCV infection accelerates HIV progression and is a leading cause of death in HIV-positive patients post-HAART introduction.
- Understanding the interplay between HIV and HCV is critical for patient management.
Purpose of the Study:
- To review the epidemiology, physiopathology, diagnostics, and treatment of HIV/HCV coinfection.
- To analyze the impact of highly active antiretroviral therapy (HAART) on HIV/HCV coinfection.
- To highlight the importance of appropriate treatment strategies for coinfected patients.
Main Methods:
- Literature review of epidemiological data.
- Analysis of physiopathological mechanisms in coinfection.
- Examination of diagnostic approaches for HIV/HCV.
- Review of current and emerging treatment options.
Main Results:
- HCV infection is common in HIV-positive populations, with accelerated disease course.
- HCV-related liver failure is a major cause of mortality in HIV patients on HAART.
- HAART has altered the landscape of opportunistic infections but highlighted HCV as a key comorbidity.
Conclusions:
- HIV/HCV coinfection requires careful management due to accelerated disease progression and increased mortality risk.
- The impact of HAART necessitates updated treatment guidelines for HCV in coinfected patients.
- Further research into optimal therapeutic interventions for HIV/HCV coinfection is warranted.
Abstract:
Hepatitis C virus (HCV) infection occurs in about one-third of HIV-seropositive patients and in about 90% of HIV-positive drug abusers. After the introduction of highly active antiretroviral therapy (HAART) and the subsequent reduction in mortality from opportunistic infections, HCV-related liver failure has become a frequent cause of death in HIV-positive patients. In HIV-seropositive patients, the course of HCV infection is accelerated and there is evidence that HCV is an important factor for HIV progression. Consequently, it is important to establish the appropriate treatment for HCV infection in HIV-seropositive patients. This review examines the epidemiology, physiopathology, diagnostics and treatment of HIV/HCV coinfection with particular regard to the impact of HAART.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Retrovirus Life Cycles
Sexually Transmitted Infections
Cytomegalovirus Disease
Viruses with RNA Genomes
